AbbVie Inc. said a clinical trial of its Venclexta (venetoclax) drug
in combination with low-dose cytarabine didn’t meet its primary endpoint
of statistically significant improvement of overall survival for
patients with acute myeloid leukemia.
Venclexta is being developed by AbbVie and Roche Holding AG.
AbbVie said results from the VIALE-C trial “are indicative of
clinical activity” for the combination. The company said the VIALE-A
trial evaluating the drug in combination with azacytidine is ongoing.
https://www.marketscreener.com/ABBVIE-INC-12136589/news/AbbVie-Venclexta-Combination-Study-Didn-t-Meet-Primary-Endpoint-30085795/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.